

PALM INTRANET

Day: Monday Date: 7/30/2007 Time: 11:17:47

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name			
Zeng	Xian-Ming	Search		

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

0

31

51

5612

2

<u>L5</u>

<u>L4</u>

<u>L3</u>

<u>L2</u>

<u>L1</u>

Freeform Search

	Database:	US Patents Full- US OCR Full-Te EPO Abstracts D JPO Abstracts D Derwent World F	xt Database Database Database	atabase							
	Term:	L6 and (phar active)	maceutical or m	edicament or	drug or						
	Display:	20 Docum	ents in <u>Display Fo</u>	ormat: CIT	Starting with	n Number 1					
Generate: O Hit List @ Hit Count O Side by Side O Image											
Search Clear Interrupt											
			Searcl	History							
DATE:	Monday,	July 30, 2007	Purge Queries	Printable Copy	Create Ca	<u>se</u>					
side by si					·	Hit Count S	et Name result set				
	ŕ		JPAB,DWPI,TDBD		OP=OR						
<u>L7</u>	•		or medicament or c	rug or active)		6	<u>L/</u>				
L6	L5 NOT	L3				29	<u>L6</u>				

((carrier or excipient) near8 (VMD or "volume median diameter"))

((Xian near Ming) near Zeng) AND @pd>20061030

L2 and ((carrier or excipient) near8 (VMD or "volume median diameter"))

END OF SEARCH HISTORY

<u>L5</u>

<u>L4</u>

<u>L3</u>

<u>L2</u>

<u>L1</u>

L4 and @ad<20020821

DB=PGPB, USPT; PLUR=YES; OP=OR

(424/46 or 424/489).ccls.

(FILE 'HOME' ENTERED AT 11:45:49 ON 30 JUL 2007)

30 JUL 2007
L1 48 S ((CARRIER OR EXCIPIENT OR LACTOSE) (8A) (VMD OR (VOLUME(W) MI
L2 4 S L1 (S) (DPI OR (DRY(W) POWDER(W) INHALER) OR INHALA? OR RESPI
L3 4 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)
L4 13 S L1 AND (MEDICAMENT OR DRUG OR ACTIVE OR BRONCHODILATOR OR FO
L5 10 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)
=> d que L1
L1 48 SEA ((CARRIER OR EXCIPIENT OR LACTOSE) (8A) (VMD OR (VOLUME(W)
MEDIAN(W) DIAMETER)))
. A m
=> d que L2 L1 48 SEA ((CARRIER OR EXCIPIENT OR LACTOSE) (8A) (VMD OR (VOLUME(W)
MEDIAN(W) DIAMETER)))
L2 4 SEA L1 (S) (DPI OR (DRY(W) POWDER(W) INHALER) OR INHALA? OR
RESPIRA?)
-1
=> d que L4
L1 48 SEA ((CARRIER OR EXCIPIENT OR LACTOSE) (8A) (VMD OR (VOLUME(W)
MEDIAN(W) DIAMETER)))
L4 13 SEA L1 AND (MEDICAMENT OR DRUG OR ACTIVE OR BRONCHODILATOR OR
FORMOTEROL OR BUDESONIDE)

ANSWER 1 OF 4 USPATFULL on STN L3

Inhalation compositions with high drug ratios TI

The invention provides a dry powder inhalation composition comprising, AB at least 0.25% by weight of the composition of an active ingredient with a particle size of less than 10 microns in diameter and a pharmaceutically acceptable particulate carrier with a particle size of less than 250 microns in diameter. Also disclosed are methods for use of the compositions of the invention with dry powder inhalers for therapeutic treatments.

2006:340303 USPATFULL ACCESSION NUMBER:

Inhalation compositions with high drug ratios TITLE:

INVENTOR(S): Zeng, Xian-Ming, Mitcham, UNITED KINGDOM

NUMBER KIND DATE -----PATENT INFORMATION: US 2006292083 A1 20061228 APPLICATION INFO.: US 2003-646362 **A**1 20030821 (10)

> NUMBER DATE _____

GB 2002-19512 20020821 PRIORITY INFORMATION:

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: IVAX CORPORATION, 4400 Biscayne Boulevard, Miami, FL,

33137, US

NUMBER OF CLAIMS: 10 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

Inhalation composition comprising formoterol and lactose TI

The invention provides a dry powder inhalation composition comprising AR medicament particles and a mixture of lactose particles with a VMD of between about 70 and about 120 μ and a diameter of less than 250 μ , the mixture being characterized in that up to 96% by weight of the lactose particles are less than 150 μ in diameter and wherein up to 25% by weight of the lactose particles are less than 5 $\boldsymbol{\mu}$ in diameter. The compns. provide for a more accurate, uniform and consistent dispersion when used with, for example, a multidose dry powder inhaler. Particle size distribution, dose delivery, and fine particle fractions for a

formoterol-lactose blend was given in an example.

2004:182664 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 140:205170

Inhalation composition comprising formoterol and TITLE:

lactose

INVENTOR(S): Zeng, Xian-Ming

PATENT ASSIGNEE(S): Ivax Corporation, USA; Norton Healthcare Ltd.

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017914	A2	20040304	WO 2003-US26385	20030821
WO 2004017914	A3	20040429		
זו. אם אר או	דית את	אבו קא זואי	RR RG RR RV R7	CA CH CN

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

```
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
              TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                   20040304 CA 2003-2499273
     CA 2499273
                           A1
                                                                         20030821
                                   20040311 AU 2003-269989
     AU 2003269989
                           A1
                                                                         20030821
                           A1
                                   20041223 US 2003-646361
                                                                         20030821
     US 2004258626
                           A1
                                   20050721 US 2003-646363
                                                                         20030821
     US 2005158248
                                  20051109 CN 2003-822405
20051130 EP 2003-751884
     CN 1694712
                           Α
                                                                         20030821
     EP 1599209
                           A2
                                                                         20030821
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                           T
     JP 2006516531
                                  20060706 JP 2004-529873
                                                                         20030821
     NZ 538965
                           Α
                                 20061130
                                              NZ 2003-538965
                                                                         20030821
                                 20050428 MX 2005-PA1903
     MX 2005PA01903
                          Α
                                                                      20050217
     ZA 2005002177
NO 2005001461
                           Α
                                 20060531 ZA 2005-2177
                                                                         20050315
                          Α
                                 20050520
                                              NO 2005-1461
                                                                         20050318
                                                GB 2002-19513
                                                                    A 20020821
PRIORITY APPLN. INFO.:
                                                GB 2002-19514
                                                                    A 20020821
                                                EP 2002-119513
                                                                    A 20020821
                                                GB 2002-19511
                                                                    A 20020821
                                                WO 2003-US26385
                                                                     A 20030821
```

- L3 ANSWER 3 OF 4 USPATFULL on STN
- TI Inhalation compositions

AB The invention provides a dry powder inhalation composition comprising medicament particles and a mixture of lactose particles with a VMD of between about 70 and about 120 microns and a diameter of less than 250 microns, the mixture being characterized in that up to 96% by weight of the lactose particles are less than 150 microns in diameter and wherein up to 25% by weight of the lactose particles are less than 5 microns in diameter. The compositions provide for a more accurate, uniform and consistent dispersion when used with, for example, a multidose dry powder inhaler

. Also disclosed are methods for use of the compositions of the invention.

ACCESSION NUMBER:

2004:326807 USPATFULL

TITLE:

Inhalation compositions

INVENTOR(S):

Zeng, Xian-Ming, Mitcham, UNITED KINGDOM

NUMBER KIND DATE _____ US 2004258626 US 2003-646361 A1 PATENT INFORMATION: 20041223

APPLICATION INFO.:

US 2003-646361 Al 20030821 (10)

NUMBER DATE ______ PRIORITY INFORMATION: GB 2002-19513 20020821 GB 2002-19513 20020821

DOCUMENT TYPE: FILE SEGMENT:

Utility

APPLICATION

LEGAL REPRESENTATIVE:

IVAX CORPORATION, 4400 Biscayne Boulevard, Miami, FL,

33137

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

12

NUMBER OF DRAWINGS:

3 Drawing Page(s)

LINE COUNT:

569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- ANSWER 4 OF 4 USPATFULL on STN L3
- Method for pulmonary and oral delivery of pharmaceuticals TI

AB In a powder formulation for use in a dry powder inhaler, a pharmaceutical acts as its own carrier, so that use of lactose or other excipients are not needed. The dry powder formulation has a single active pharmaceutical compound having two major populations in particle size distribution: microfine particles of the active pharmaceutical, of 1-10 microns in diameter, and larger carrier particles, also of the active pharmaceutical compound. The carrier particles provide a long acting, delayed onset, and optionally therapeutic effect via the GI tract, while the microfine particles provide a fast onset effect via the lung.

ACCESSION NUMBER: 2001:205432 USPATFULL

TITLE: Method for pulmonary and oral delivery of

pharmaceuticals

INVENTOR(S): Ward, Gary, San Diego, CA, United States

Schultz, Robert, San Diego, CA, United States

PATENT ASSIGNEE(S): Dura Pharmaceuticals, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2001041190 A1 20011115

US 6616914 B2 20030909

APPLICATION INFO.: US 2001-907393 A1 20010717 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-480549, filed on 10 Jan

2000, UNKNOWN

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS

ANGELES, CA, 90071

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 319

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
- TI Agglomerate Strength and Dispersion of Salmeterol Xinafoate from Powder Mixtures for Inhalation
- AB The study investigated the role of agglomeration and the effect of fine lactose size on the dispersion of salmeterol xinafoate (SX) from SX-lactose mixts. for inhalation. Particle size distributions were characterized by Malvern Mastersizer S, Aerosizer and Spraytec, and imaging conducted by SEM. Inter-particulate adhesion was quantified by atomic force microscopy. Deposition of SX was measured using a twin stage impinger. SX was analyzed using validated high-performance liquid chromatog. method (r2=1.0, CV=0.4-1.0%). Addition of fine lactose with a vol. median diam. (VMD) of

7.9 µm to a SX- lactose carrier and carrier-free mixture resulted in significantly better dispersion (16.8% for 20% added fine lactose) than fractions with VMD of 3.0, 17.7 and 33.3 µm (less than 9.1% for 20% fine lactose). Using the carrier-free mixts., particle sizing of the aerosol cloud using the Spraytec, coupled with the application of the Aerosizer using differing dispersion energies and SEMs of the samples, indicated that an open packed, agglomerate structure improved SX dispersion. The highest extent of SX dispersion occurred when SX and fine lactose were detached from the surface, usually in the form of loose agglomerates. The outcomes of this research demonstrated how agglomerate structure influenced dispersion and the key role of fine lactose particle size in SX dispersion from mixts. for inhalation.

ACCESSION NUMBER: 2006:1163978 CAPLUS

DOCUMENT NUMBER: 146:32717

TITLE: Agglomerate Strength and Dispersion of Salmeterol

Xinafoate from Powder Mixtures for Inhalation

AUTHOR(S): Adi, Handoko; Larson, Ian; Chiou, Herbert; Young,

Paul; Traini, Daniela; Stewart, Peter

CORPORATE SOURCE: Department of Pharmaceutics, Victorian College of

Pharmacy, Monash University, Parkville, 3052,

Australia

SOURCE: Pharmaceutical Research (2006), 23(11), 2556-2565

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 USPATFULL on STN

TI Method of preparing dry powder inhalation compositions

AB The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.

ACCESSION NUMBER: 2005:182865 USPATFULL

TITLE: Method of preparing dry powder inhalation compositions

INVENTOR(S): Zeng, Xian-Ming, Surrey, UNITED KINGDOM

PRIORITY INFORMATION: GB 2002-19511 20020821 GB 2002-19513 20020821

GB 2002-19513 20020821

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

IVAX CORPORATION, 4400 Biscayne Boulevard, Miami, FL, LEGAL REPRESENTATIVE:

33137, US

NUMBER OF CLAIMS: 15 EXEMPLARY CLAIM: 1 LINE COUNT: 484

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Inhalation composition comprising formoterol and lactose AB The invention provides a dry powder inhalation composition comprising

medicament particles and a mixture of lactose particles with a VMD of between about 70 and about 120 $\boldsymbol{\mu}$ and a diameter of less than 250 μ , the mixture being characterized in that up to 96% by weight of the lactose particles are less than 150 μ in diameter and wherein up to 25% by weight of the lactose particles are less than 5 μ in diameter. The compns. provide for a more accurate, uniform and consistent dispersion when used with, for example, a multidose dry powder inhaler. Particle size distribution, dose delivery, and fine particle fractions for a formoterol-lactose blend was given in an example.

ACCESSION NUMBER: 2004:182664 CAPLUS

DOCUMENT NUMBER: 140:205170

TITLE: Inhalation composition comprising formoterol

and lactose

INVENTOR(S): Zeng, Xian-Ming

PATENT ASSIGNEE(S): Ivax Corporation, USA; Norton Healthcare Ltd.

PCT Int. Appl., 23 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC: NUM. COUNT: 2

PATENT INFORMATION: DAMENIA NO

PA'	PATENT NO.				KIND DATE			APPLICATION NO.					DATE				
	WO 2004017914								WO 2	003-1	US26:	385		20030821			
WO	WO 2004017914				A3		2004	0429									
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
								IS,									
		•		•	•	•	•	MG,		•	•	•		•		•	·-
				•	•	•		SC,					•				
		•		•	•	•	•	VC,			•	•	•	,	,	,	,
	RW.	GH,		•	•	•	•	•			•	•		7.W .	AM.	A7.	BY.
	2000	•	•	•	•	•	•	AT,	•	•	•	•	•	•	•	•	•
		•	•	•	•	•	•	IT,	•	•	•	•	•	•	•	•	•
		•	•	•	•	•	•	GA,						•		-	·=
CA	2400	•		•	•			0304			-	-	-	-			
	2499																
	2003																
	2004																
	2005																
	1694							1109									
EP	1599							1130					-				
	R:	AΤ,	•	•	•	•	•	•	•		•	•			•	•	PT,
		•	•		•	•		MK,			•						
JP	JP 2006516531 T 2006070					JP 2004-529873						20030821					
NZ	5389	65			Α		2006	1130		NZ 2	003-	5389	65		2	0030	821
MX	2005	PA01	903		A		2005	0428		MX 2	005-	PA19	03		2	0050	217
ZA	2005	0021	77		Α		2006	0531		ZA 2	005-	2177			2	0050	315
NO	2005	0014	61		Α		2005	0520		NO 2	005-	1461			2	0050	318
PRIORIT	PRIORITY APPLN. INFO.:			. :						GB 2	002-	1951	3		A 2	0020	821
										GB 2	002-	1951	4		A 2	0020	821

EP 2002-119513 A 20020821 GB 2002-19511 A 20020821 WO 2003-US26385 A 20030821

L5 ANSWER 5 OF 10 USPATFULL on STN

TI Inhalation compositions

AB The invention provides a dry powder inhalation composition comprising medicament particles and a mixture of lactose

particles with a VMD of between about 70 and about 120 microns and a diameter of less than 250 microns, the mixture being characterized in that up to 96% by weight of the lactose particles are less than 150 microns in diameter and wherein up to 25% by weight of the lactose particles are less than 5 microns in diameter. The compositions provide for a more accurate, uniform and consistent dispersion when used with, for example, a multidose dry powder inhaler. Also disclosed are methods

for use of the compositions of the invention.

ACCESSION NUMBER:

PATENT INFORMATION:

2004:326807 USPATFULL Inhalation compositions

INVENTOR (S):

TITLE:

Zeng, Xian-Ming, Mitcham, UNITED KINGDOM

NUMBER KIND DATE
US 2004258626 A1 20041223

APPLICATION INFO.: US 2003-646361 A1 20030821 (10)

NUMBER DATE

PRIORITY INFORMATION: GB 2002-19513 20020821 GB 2002-19513 20020821

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: IVAX CORPORATION, 4400 Biscayne Boulevard, Miami, FL,

33137

NUMBER OF CLAIMS: 12 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.